174 related articles for article (PubMed ID: 36209091)
1. Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.
Jaafarinia A; Kafami B; Sahebnasagh A; Saghafi F
BMC Complement Med Ther; 2022 Oct; 22(1):262. PubMed ID: 36209091
[TBL] [Abstract][Full Text] [Related]
2. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial.
Sattarinezhad A; Roozbeh J; Shirazi Yeganeh B; Omrani GR; Shams M
Diabetes Metab; 2019 Jan; 45(1):53-59. PubMed ID: 29983230
[TBL] [Abstract][Full Text] [Related]
4. Crocin mediated amelioration of oxidative burden and inflammatory cascade suppresses diabetic nephropathy progression in diabetic rats.
Abou-Hany HO; Atef H; Said E; Elkashef HA; Salem HA
Chem Biol Interact; 2018 Mar; 284():90-100. PubMed ID: 29409856
[TBL] [Abstract][Full Text] [Related]
5. Crocin Ameliorates Diabetic Nephropathy through Regulating Metabolism, CYP4A11/PPARγ, and TGF-β/Smad Pathways in Mice.
Chen W; Su J; Liu Y; Gao T; Ji X; Li H; Li H; Wang Y; Zhang H; Lv S
Curr Drug Metab; 2023; 24(10):709-722. PubMed ID: 37936469
[TBL] [Abstract][Full Text] [Related]
6. Supplementation of conventional anti-diabetic therapy with alpha-lipoic acid prevents early development and progression of diabetic nephropathy.
Dugbartey GJ; Alornyo KK; N'guessan BB; Atule S; Mensah SD; Adjei S
Biomed Pharmacother; 2022 May; 149():112818. PubMed ID: 35286963
[TBL] [Abstract][Full Text] [Related]
7. Effect of crocin on diabetic patients: A placebo-controlled, triple-blinded clinical trial.
Sepahi S; Golfakhrabadi M; Bonakdaran S; Lotfi H; Mohajeri SA
Clin Nutr ESPEN; 2022 Aug; 50():255-263. PubMed ID: 35871933
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of saffron (its active constituent, crocin) on nephropathy in streptozotocin-induced diabetic rats.
Altinoz E; Oner Z; Elbe H; Cigremis Y; Turkoz Y
Hum Exp Toxicol; 2015 Feb; 34(2):127-34. PubMed ID: 24925368
[TBL] [Abstract][Full Text] [Related]
9. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory markers response to crocin supplementation in patients with type 2 diabetes mellitus: A randomized controlled trial.
Behrouz V; Sohrab G; Hedayati M; Sedaghat M
Phytother Res; 2021 Jul; 35(7):4022-4031. PubMed ID: 33856733
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of Circulating Stress Markers, Inflammatory Cytokines and Decreased Antioxidant Level in Diabetic Nephropathy.
Mansoor G; Tahir M; Maqbool T; Abbasi SQ; Hadi F; Shakoori TA; Akhtar S; Rafiq M; Ashraf M; Ullah I
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363561
[No Abstract] [Full Text] [Related]
12. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant for treatment of diabetic nephropathy: A systematic review and meta-analysis.
Kandhare AD; Mukherjee A; Bodhankar SL
Chem Biol Interact; 2017 Dec; 278():212-221. PubMed ID: 29108777
[TBL] [Abstract][Full Text] [Related]
14. A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease.
Koay YY; Tan GCJ; Phang SCW; Ho JI; Chuar PF; Ho LS; Ahmad B; Abdul Kadir K
Nutrients; 2021 Jan; 13(1):. PubMed ID: 33477404
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
[TBL] [Abstract][Full Text] [Related]
17. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
Khajehdehi P; Pakfetrat M; Javidnia K; Azad F; Malekmakan L; Nasab MH; Dehghanzadeh G
Scand J Urol Nephrol; 2011 Nov; 45(5):365-70. PubMed ID: 21627399
[TBL] [Abstract][Full Text] [Related]
18. The effect of L-thyroxine substitution on oxidative stress in early-stage diabetic nephropathy patients with subclinical hypothyroidism: a randomized double-blind and placebo-controlled study.
Chen Y; Wu G; Xu M
Int Urol Nephrol; 2018 Jan; 50(1):97-103. PubMed ID: 29196928
[TBL] [Abstract][Full Text] [Related]
19. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
20. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
